Market Overview

Teva Has Potential For 6% CAGR Ahead, UBS Says In Upgrade

Teva Has Potential For 6% CAGR Ahead, UBS Says In Upgrade
Related TEVA
The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
Q4 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
FDA backs exclusivity of Eagle Pharma's Bendeka until late 2022 (Seeking Alpha)

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) stock is down 73 percent from its 2015 peak — and it's nearly struck bottom, with recovery just around the corner, in UBS' view. 

The Analyst

Analyst Navin Jacob upgraded Teva from Neutral to Buy and raised the price target from $23 to $24.

The Thesis

By Jacob’s account, the Street is overestimating Teva’s risk in paying down its debt and exaggerates the potential pain from cost-cutting measures.

UBS expects the latter to have no effect on sales, the analyst said in a Tuesday note. 

“Our detailed analysis of TEVA's costs (review of facility footprint, headcount sizing and R&D costs) not only supports management goals but also highlights potential peak savings of $3.6 billion." 

Jacob estimates a performance trough in 2019 followed by bottom-line compound annual growth of 6 percent over the following three years.

Throughout that term, the analyst forecast $3.6 billion in expense savings and expects Austedo, Ajovy and biosimilar products to offset $1.2 billion in Copaxone and ProAir erosion. Generics price erosion in the U.S. is expected to wane from 8 percent in 2019 to 5 percent in 2023, and Herceptin and Rituxan biosimilars are seen to offset remaining pressure, Jacob said. 

The factors should drive bottom-line stabilization and press leverage closer to 3x in 2022, according to UBS. 

Price Action

Teva shares were trading up 4.21 percent to $19.54 at the time of publication Wednesday. 

Related Links:

Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year

BTIG Says Buy The Dip In Medtronic

Latest Ratings for TEVA

Feb 2019Credit SuisseMaintainsNeutralNeutral
Feb 2019Raymond JamesUpgradesMarket PerformOutperform
Jan 2019PiperJaffrayUpgradesUnderweightNeutral

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Navin Jacob UBSAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (TEVA)

View Comments and Join the Discussion!

EUR/USD Forecast: 3 Reasons Why Bears Have The Upper Hand

CBD, Still A Restricted Substance